Company news
Apogee Therapeutics, Inc. (NASDAQ:APGE) news
Apogee Therapeutics, Inc. news releases on 6ix. Latest, Jun 22, 2026: AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
Press releases & updates
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
June 21, 2026
Apogee Therapeutics to Participate in Upcoming June Conferences
May 28, 2026
Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis
May 26, 2026
Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart
May 26, 2026
Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026
May 26, 2026
Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results
May 11, 2026
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million
March 25, 2026
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
March 23, 2026
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
March 22, 2026
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis
March 22, 2026
Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026
March 21, 2026
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results
March 1, 2026
Apogee Therapeutics to Participate in Upcoming March Conferences
February 24, 2026
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026
February 4, 2026
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook
January 5, 2026
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026
January 4, 2026
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
November 9, 2025
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody
November 9, 2025
Apogee Therapeutics to Participate in Upcoming Conferences
November 2, 2025
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million
October 13, 2025
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million
October 9, 2025
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
October 7, 2025
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering
October 7, 2025
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
September 10, 2025
Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum
September 2, 2025
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
August 10, 2025
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
July 6, 2025
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
July 5, 2025
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
May 28, 2025
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
May 11, 2025
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
May 11, 2025
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference
April 30, 2025
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results
March 2, 2025
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)
March 2, 2025
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
February 27, 2025
Apogee Therapeutics to Participate in Upcoming March Investor Conferences
February 24, 2025
Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis
February 2, 2025
Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference
January 28, 2025
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions
December 9, 2024
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day
December 1, 2024
Apogee Therapeutics Announces Agenda for Virtual R&D Day
November 28, 2024
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
November 17, 2024
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results
November 11, 2024
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
November 3, 2024
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
October 23, 2024
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
October 15, 2024
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
September 11, 2024
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
September 8, 2024
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
August 18, 2024
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results
August 11, 2024